A Phase 3 interventional study of Tezepelumab in Chronic Rhinosinusitis With Nasal Polyps, sponsored by AstraZeneca. Recruiting at 45 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies in Nasal Polyps with a site in China — 17 open to participants now, 24 under way, 7 of them phase 3. Nasal Polyps · China.
Among the 46 studies in Nasal Polyps with a site in China, this one is the 10th largest by planned enrollment of the 43 interventional ones that give a count, is one of 10 that started in 2026, is one of 14 in phase 3, reaches primary completion later than 19 of the 23 other live ones, and was the 42nd registered.
236 studies on the registry are indexed under Nasal Polyps; 68 are open to participants now.
Browse Nasal Polyps studies →17 of the 46 studies in Nasal Polyps with a site in China are open now. Recruiting first, the newest first:
Bambusa Therapeutics · Sites in China
Ages 18–75 · Healthy volunteers
Tang-Du Hospital · Sites in China
Ages 18–65
Guangdong Hengrui Pharmaceutical Co., Ltd · Sites in China
Ages 18–75
The Affiliated Hospital of Qingdao University · Sites in China
Ages 18–65
Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 40 Nasal Polyps studies recruiting now, 22 (55%) set no upper age limit and 12 (30%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 16 · Phase 3 15 · Phase 4 4
First in 2010; this study’s year is marked. 10 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 230 is above the median of 60 across 181 interventional studies indexed under Nasal Polyps.
Median enrollment 90 across the 43 interventional studies, 146 across the 3 observational. Of the 17 that completed or were terminated, 6 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 46 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
AstraZeneca has 8 studies filed under Nasal Polyps — fewer than ten, so there is no comparison to draw.
6 of the studies in Nasal Polyps with a site in China that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07424144Phase 3SanofiAn Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps | 2027-02-17 |
| NCT07107256Phase 3Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.Clinical Trial of TQC2731 Injection in Patients With Chronic Sinusitis and Nasal Polyps | 2027-03 |
| NCT06338995Phase 3Eli Lilly and CompanyA Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP) | 2027-05 |
| NCT07313917Longbio PharmaA Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | 2027-02-28 |
| NCT07755371AkesoA Study to Evaluate the Efficacy and Safety of AK139 in Participants With Chronic Rhinosinusitis With Nasal Polyps | 2027-04-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 46 studies in Nasal Polyps with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicentre, open-label, single-arm, Phase 3b study to assess nasal polyps score and symptoms in Chinese adult participants with chronic rhinosinusitis with nasal polyposis initiating treatment with tezepelumab.
This is a multicentre, open-label, single-arm, Phase 3b study to assess nasal polyps score and symptoms in Chinese adult participants with chronic rhinosinusitis with nasal polyposis initiating treatment with tezepelumab.
The study aims to enrol approximately 230 participants from approximately 30-50 sites in China. To ensure that participants' inflammatory endotypes of disease are represented appropriately in this study, restrictive inclusion criteria will be adopted to ensure that all participants have an eosinophilic endotype (defined by JESREC score of ≥ 11), with approximately 30% of participants having a JESREC score of ≥ 15. Eligible participants will receive tezepelumab at a fixed dose of 210 mg subcutaneously (SC) using an accessorised pre-filled syringe (APFS) every four weeks for up to 24 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Age
1. Participant must be 18 years of age or older, at the time of signing the .
SNOT-22 total score ≥ 30 as assessed at screening. 3. Any standard of care for treatment of CRSwNP, which must include treatment with intranasal , provided the participant is stable on that treatment for at least 30 days prior to Visit 1. Investigators should also ensure that participants are compliant and on a stable dose of the background INCS during study period.
4. Either 1) documented treatment of NP exacerbation with SCS for at least 3 consecutive days or one IM depo-injectable dose (or /intolerance or intolerance to surgery) within the past 12 months prior to Visit 1 but not within the last 3 months prior to Visit 1 OR 2) any history of NP surgery (or contraindications/intolerance or intolerance to surgery).
5. Participants with JESREC score of ≥ 11.
Female participants:
The following age-specific requirements apply:
WOCBP must be willing to use one of the methods of contraception described hereafter, from the time of signing the ICF throughout the study and 16 weeks after last tezepelumab administration:
Exclusion Criteria:
Participants are excluded from the study if any of the following criteria apply:
-Medical Conditions
Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric, or major physical impairment that is not stable in the opinion of the investigator and could:
Participants with conditions or concomitant disease that makes them non-evaluable for the primary CRSwNP endpoints such as:
History of cancer:
Infection requiring systemic antibiotics within 14 days prior to Visit 1. Note: Participants with respiratory infections requiring antibiotics within 14 days prior to Visit 1 may extend their screening period to allow recovery and return no sooner than 14 days after completion of therapy.
-Prior/Concomitant Therapy
Recent aspirin desensitisation within 6 months of enrolment.
-Prior/Concurrent Clinical Study Experience
Concurrent enrolment in another clinical study involving a study intervention.
-Diagnostic Assessments
Positive surface antigen, or antibody serology at screening, or a positive medical history for hepatitis B or C. Participants with a history of hepatitis B vaccination without a history of hepatitis B are allowed to participate.
-Other Exclusions
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This is a multicentre, open-label, single-arm, Phase 3b study, all participants will be grouped into the same group for the study intervention.
Drug: Tezepelumab
At Visit 2 (Week 0), participants who meet the inclusion and exclusion criteria will receive tezepelumab treatment. All participants will receive tezepelumab 210 mg SC every four weeks (Q4W) from Week 0 (Visit 2), with the last dose administered at Week 20 (Visit 7). All tezepelumab administration will occur at the study site. Each participant who completes the study without discontinuing study intervention will receive a total of 6 doses of tezepelumab.
Also known as: TEZSPIRE®
To describe changes from baseline in nasal polyp score (NPS)
Change from baseline in total NPS evaluated by nasal endoscopy at Week 24 NPS: score 0-4 for each item, 4 indicates worse outcome
Time frame: baseline-week24
To describe changes from baseline in participant-reported nasal congestion as evaluated by nasal congestion score (NCS)
Change from baseline in bi-weekly mean nasal congestion score (NCS) evaluated as part of the Nasal Polyposis Symptom Diary (NPSD) at Week 24. NCS: score 0-3, 3 indicates worse outcome
Time frame: baseline-week24
To describe responder proportion in participant-reported nasal congestion as evaluated by the NCS following initiation of tezepelumab treatment
Proportion of NCS responders (minimal clinically important difference \[MCID\] from baseline = -1.0) at each collected timepoint. NCS: score 0-3, 3indicates worse outcome
Time frame: Daily for the 2 weeks prior to Week 0 through end of treatment visit (EOT; Week 24)
To describe time to response and changes in participant-reported nasal congestion as evaluated by the NCS following initiation of tezepelumab treatment
Description of time to first response for NCS. NCS: score 0-3, 3indicates worse outcome
Time frame: Daily for the 2 weeks prior to Week 0 through end of treatment visit (EOT; Week 24)
To describe changes in participant-reported nasal congestion as evaluated by the NCS following initiation of tezepelumab treatment
Change from baseline in NCS at each collected timepoint in daily score. NCS: score 0-3, 3indicates worse outcome
Time frame: Daily for the 2 weeks prior to Week 0 through end of treatment visit (EOT; Week 24)
To describe responder proportion in NPS following initiation of tezepelumab treatment
Proportion of participants with (i) ≥ 1 point reduction and (ii) ≥ 2 points reduction in NPS at Week 24. NPS: score 0-4 for each item, 4 indicates worse outcome
Time frame: Baseline, Weeks 0, 4, 12, and 24
To describe time to response in NPS following initiation of tezepelumab treatment
Description of time to first response for NPS (≥ 1 point reduction) NPS: score 0-4, 4 indicates worse outcome
Time frame: Baseline, Weeks 0, 4, 12, and 24
To describe changes in NPS following initiation of tezepelumab treatment
Change from baseline over time in NPS evaluated by nasal endoscopy through Week 24. NPS: score 0-4, 4 indicates worse outcome
Time frame: Baseline, Weeks 0, 4, 12, and 24
To describe numbers of CRSwNP exacerbation following initiation of tezepelumab treatment
* Description of numbers of CRSwNP exacerbation during treatment period (Week 0 to 24) at Week 24 * Description of annualized CRSwNP exacerbation rate
Time frame: Baseline, Weeks 0, 4, 12, and 24
To describe responder proportion in sino-nasal symptoms as evaluated by sino-nasal outcome test, 22 item (SNOT-22) total score following initiation of tezepelumab treatment
Proportion of SNOT-22 responder (MCID from baseline=-8.9) at each collected timepoint. SNOT-22: score 0-5 for each item, 5 means worse outcome
Time frame: Baseline, Weeks 0, 4, 8, 12, 16, 20, and 24
To describe time to first response in sino-nasal symptoms as evaluated by sino-nasal outcome test, 22 item (SNOT-22) total score following initiation of tezepelumab treatment
Description of time to first response for SNOT-22. SNOT-22: score 0-5 for each item, 5 means worse outcome
Time frame: Baseline, Weeks 0, 4, 8, 12, 16, 20, and 24
To describe changes in sino-nasal symptoms as evaluated by sino-nasal outcome test, 22 item (SNOT-22) total score following initiation of tezepelumab treatment
Change from baseline in SNOT-22 at each collected timepoint. SNOT-22: score 0-5 for each item, 5 means worse outcome
Time frame: Baseline, Weeks 0, 4, 8, 12, 16, 20, and 24
To describe changes in nasal blockage (NB) as evaluated by peak nasal inspiratory flow (PNIF)
Change from baseline visit in NB measured by PNIF. Higher PNIF values indicate improved nasal airflow.
Time frame: Weeks 0, 4, 12, and 24
To describe responder proportion in nasal blockage (NB) as evaluated by peak nasal inspiratory flow (PNIF)
Proportion of PNIF responder (MCID from baseline = 20 L/min)
Time frame: Weeks 0, 4, 12, and 24
To describe time to responder in nasal blockage (NB) as evaluated by peak nasal inspiratory flow (PNIF)
Description of time to first response for PNIF
Time frame: Weeks 0, 4, 12, and 24
To describe responder proportion in sense of smell as evaluated as part of the NPSD
* Change from baseline in bi-weekly mean loss of smell evaluated as part of the NPSD at Week 24 * Changes from baseline in loss of smell at all collected time points (daily)
Time frame: Baseline-Week24
To describe time to responder in sense of smell as evaluated as part of the NPSD.
* Change from baseline in bi-weekly mean loss of smell evaluated as part of the NPSD at Week 24 * Changes from baseline in loss of smell at all collected time points (daily)
Time frame: Baseline-Week24
To describe changes in sense of smell as evaluated as part of the NPSD
* Change from baseline in bi-weekly mean loss of smell evaluated as part of the NPSD at Week 24 * Changes from baseline in loss of smell at all collected time points (daily)
Time frame: Baseline-Week24
To describe responder proportion in sleep as evaluated by SNOT-22 sleep domain following initiation of tezepelumab treatment
Proportion of SNOT-22 sleep domain responders (MCID from baseline = -2.9). SNOT-22: score 0-5 for each item, 5 means worse outcome
Time frame: Baseline, Weeks 0, 4, 8, 12, 16, 20, and 24
To describe time to responder in sleep as evaluated by SNOT-22 sleep domain following initiation of tezepelumab treatment
Description of time to first response for SNOT-22 sleep domain . SNOT-22: score 0-5 for each item, 5 means worse outcome
Time frame: Baseline, Weeks 0, 4, 8, 12, 16, 20, and 24
To describe changes in sleep as evaluated by SNOT-22 sleep domain following initiation of tezepelumab treatment
Changes from baseline in SNOT-22 sleep domain score。 SNOT-22: score 0-5 for each item, 5 means worse outcome
Time frame: Baseline, Weeks 0, 4, 8, 12, 16, 20, and 24
To describe responder proportion in overall symptoms as evaluated by NPSD total nasal symptom score (TSS) following initiation of tezepelumab
Proportion of TSS responder (MCID from baseline = -4.0)
Time frame: Daily for the 2 weeks prior to Week 0 and through EOT (Week 24)
To describe time to responder in overall symptoms as evaluated by NPSD total nasal symptom score (TSS) following initiation of tezepelumab
Description of time to first response for TSS
Time frame: Daily for the 2 weeks prior to Week 0 and through EOT (Week 24)
To describe changes in overall symptoms as evaluated by NPSD total nasal symptom score (TSS) following initiation of tezepelumab
Changes from baseline in TSS in daily score
Time frame: Daily for the 2 weeks prior to Week 0 and through EOT (Week 24)
To describe the change on sinus opacification following initiation of tezepelumab.
Change from baseline in Lund-Mackay score (LMK) evaluated by CT at Week 24 as determined by the central reader. Lund-Mackay score: 0-12 each item, 12 means worse outcome
Time frame: Baseline, Week 24
To describe the change in lung function with co-morbid asthma following initiation of tezepelumab.
Change from baseline in pre-BD FEV1 at Week 24
Time frame: Baseline, Week12, Week24
To describe the change in ACQ-5 in participants with co-morbid asthma following initiation of tezepelumab.
* Change from baseline in ACQ-5 at Week 24. * The ACQ-5 total score is the mean of the 5 responses. Mean scores of ≤ 0.75 indicate well-controlled asthma, scores between 0.75 and \< 1.5 indicate partly controlled asthma, and a score ≥ 1.5 indicates not well-controlled asthma. Individual changes of at least 0.5 are considered to be clinically meaningful.
Time frame: Baseline and 24
To describe the change in asthma exacerbation in participants with co-morbid asthma following initiation of tezepelumab.
Description of numbers of asthma exacerbation in participants with comorbid asthma during treatment period (Week 0-24) at Week 24
Time frame: week0-24
To describe the change in asthma exacerbation in participants with co-morbid asthma following initiation of tezepelumab.
Description of AAER in participants with comorbid asthma
Time frame: week0-24
To evaluate the safety and tolerability of tezepelumab
Adverse events (AEs), Serious adverse events(SAEs), Discontinuations of study intervention due to an AE(DAEs), AE of special interest(AESIs)
Time frame: week0-24
To evaluate the need for nasal polyp surgery up to Week 24
Time to NP surgery decision up to Week 24
Time frame: Baseline-Week24
To evaluate the need for SCS use up to Week 24
Description of SCS use up to Week 24
Time frame: Baseline-Week24
To evaluate the changes in key type 2 inflammatory mediators in the serum following initiation of tezepelumab
Changes in concentration levels of inflammatory cytokines \[TT22.1\]\[AX22.2\]in serum from baseline to Week 24: IL-5, IL-13, EDN by ELISA, summarized by mean change
Time frame: Baseline and the Week 24
To evaluate changes in local tissue immune cell infiltration and systemic inflammatory markers in the serum following initiation of tezepelumab
Changes in cell counts of granulocytes in nasal polyp tissue biopsy from baseline to Week 24 by HE staining: eosinophils and neutrophils
Time frame: Baseline and the Week 24
To evaluate changes in local tissue immune cell infiltration and systemic inflammatory markers in the serum following initiation of tezepelumab
Changes in concentration levels of inflammatory cytokines in serum from baseline to Week 24: IL-33, TSLP, IL-25, amphiregulin, Eotaxin 1, Eotaxin 2, Eotaxin 3, CCL17, IL-17, IL-22, IFN-γ, IL-6, IL-8, Periostin, and GZMK\[QZ23.1\]\[AX23.2\],summarized by mean change.
Time frame: Baseline and the Week 24
To further elucidate the underlying mechanisms of tezepelumab treatment and to identify predictive biomarkers for treatment response.
Changes in the percentage (%) of peripheral blood memory T cell and ILC2 populations by flow cytometry-based assessment
Time frame: Baseline, Weeks 12 and 24
To further elucidate the underlying mechanisms of tezepelumab treatment and to identify predictive biomarkers for treatment response.
Changes in nasal microbiome composition by 16S rRNA sequencing from nasal swabs
Time frame: Baseline and Week 24
To further elucidate the underlying mechanisms of tezepelumab treatment and to identify predictive biomarkers for treatment response.
Changes in the transcriptomic profile and gene expression levels by RNA sequencing from baseline to Week 24: IL-33, TSLP, IL-25, amphiregulin, CCL17, Periostin, GZMK, and neuropeptides
Time frame: Baseline and Week 24
To further elucidate the underlying mechanisms of tezepelumab treatment and to identify predictive biomarkers for treatment response.
Changes in concentration levels of inflammatory cytokines in nasal secretion from baseline \[QZ25.1\]\[AX25.2\]to Week 24: IL-5, IL-13, IL-33, TSLP, IL-25, Amphiregulin, Eotaxin 1, Eotaxin 2, Eotaxin 3, CCL17, IL-17, IL-22, IFN-γ, IL-6, IL-8, Periostin, GZMK, EDN, and neuropeptides
Time frame: Baseline and Week 24
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment:https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
Supporting information: Study protocol
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved, AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Mar 2028, 22 months after the start.
Of 30 industry-sponsored phase 3 interventional studies under Nasal Polyps, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 26. This study's planned 22 months is close to that.
Counting every sponsor, half of 34 studies reached it within 22 months; a quarter within 19 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tezepelumab